Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

Two Phase 3 Trials of Baricitinib for Alopecia Areata

(2022) Brett King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

(2021) Peter C Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

The Alopecia Areata Investigator’s Global Assessment (AA‐IGA™) Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials

(2020) K.W. Wyrwich et al.   BRITISH JOURNAL OF DERMATOLOGY

Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata

(2020) Kathleen W. Wyrwich et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

JAK inhibitors for alopecia areata: a systematic review and meta-analysis

(2019) Kevin Phan et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

JAK inhibitors in dermatology: The promise of a new drug class

(2017) William Damsky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE